Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Sionna Therapeutics and Odyssey Therapeutics have joined Metsera and Maze in an attempt to go public via the still rocky IPO route. The biotechs, focused
The China-to-US experimental medicine pipeline is ballooning: yet another US-based biotech formed around a candidate from China’s Keymed Biosciences on Monday. Life sciences investment firm
SAN FRANCISCO — Ben Auspitz, a veteran biotech investor and repeat entrepreneur, is reuniting with longtime collaborator Alexis Borisy and his “free the founders” …
Eli Lilly, the most talked-about pharmaceutical company in recent years, is buying cancer startup Scorpion Therapeutics about half a year after its Sign up to
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Four new biotechs launched Friday with megarounds and in-licensed treatment candidates, giving the industry an $800 million boost ahead of the year’s biggest dealmaking event
Two biotechs emerged on Friday with assets from Keymed Biosciences, extending a proliferating trend of Western investors propping up new companies to further develop assets
Shoreline Biosciences, a gene editing and cell therapy biotech, has let go of staffers dedicated to a cell therapy project that’s working with Gilead’s Kite
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS